Biosyent Inc. · TSXV:RX
Biosyent — Q4 2023 Earnings Presentation
19 slides from Biosyent's earnings presentation, Mar 13, 2024
Slide 1: BioSyent Inc. Q4 / FY 2023 Results
BioSyent BioSyentInc. Inc. Q4 Q4//FY FY2023 2023Results Results MARCH MARCH13, 13,2024 2024 PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX 3 | www.biosyent.com | TSXV: RX
Slide 4: Q4 / FY 2023 Sales Summary ($)
Q4 / FY 2023 Sales Summary ($) Q4 ‘23 Q4 ‘23 vs. FY ‘23 FY ‘23 vs. Sales ($) Q4 ’22 (%) Sales ($) FY ’22 (%) Canadian Pharma ($) $7,989k +10% $29,555k +13% FeraMAX® Pd +9% +13% RepaGyn® +7% +3% Tibella® +36% +46% Combogesic® (71%) (53%) Inofolic® n/a n/a Cathejell® +10% +5% Gelclair® n/a n/a Interna
Slide 5: Sales, EBITDA and NIAT - Q4
Sales, EBITDA and NIAT Quarter (Q4) ended December 31, 2023 9,000 +11% Sales 8,000 +3% +35% +10% Canadian Pharma +26% (54%) International Pharma 7,000 +317% Legacy 6,000 EBITDA / NIAT • EBITDA Margin CAD (000's) 5,000 Q4 2023: 20% to Sales 4,000 Q4 2022: 21% to Sales +136% 3,000 • NIAT Margin +182%
Slide 6: Sales, EBITDA and NIAT - Full Year
Sales, EBITDA and NIAT Full Year (FY) ended December 31, 2023 +13% Sales +28% 30,000 -2% +13% Canadian Pharma +35% +53% International Pharma 25,000 0% Legacy EBITDA / NIAT 20,000 • EBITDA Margin FY 2023: 25% to Sales CAD (000's) 15,000 FY 2022: 27% to Sales 10,000 +57% +7% • NIAT Margin -15% +66% +1
Slide 7: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS 54 Consecutive Profitable Quarters Q4 2023 $1,450,791 $0.12 to Q4 2023 Q3 2023 $2,350,900 $0.20 $0.53 TTM Q2 2023 $1,483,190 $0.12 Q1 2023 $1,175,246 $0.10 Q4 2022 $1,199,516 $0.09 Q3 2022 $1,453,042 $0.12 $0.44 TTM Q2 2022 $1,217,883 $0.10 Q
Slide 8: 14 Years of Profitable Growth (and Counting!)
14 Years of Profitable Growth (and Counting!) 35,000 Annual Revenue Annual NIAT 30,000 25,000 CAD 000'S 20,000 15,000 10,000 5,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 *2024* f/d shares: 14,336,194 11,968,767 8 | www.biosyent.com | TSXV: RX
Slide 9: Q4 2023 Highlights
Q4 2023 Highlights ▪ Distribution of Gelclair® commenced ▪ menopauseinformation.ca launched ▪ 5th consecutive quarterly dividend of $0.04 paid ▪ 93,400 shares repurchased under NCIB Subsequent to Q4 2023 ▪ Increased quarterly dividend of $0.045 declared ▪ BioSyent named to 2024 TSX Venture 50 ▪ Laun
Slide 10: Most recommended iron supplement in Canada
▪ Most recommended iron supplement in Canada - pharmacists and physicians - 8 consecutive years(1) ▪ Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2022 Survey on OTC Counselling and Recomme
Slide 11: FeraMAX LifeCycle Strategy
FeraMAX® LifeCycle Strategy ▪ Expanding leadership of FeraMAX® brand in Canada: “Iron health for life” ▪ FeraMAX® Pd platform introduced in October 2020 ▪ Patented delivery system based on Polydextrose Iron Complex (PDIC) ▪ Foundation for future product development ▪ Incremental share and revenue ▪
Slide 12: NEW in 2023 - FeraMAX Pd Maintenance 45
NEW in 2023 - FeraMAX® Pd Maintenance 45 ▪ Developed by BioSyent ▪ 3rd product incorporating PDIC ▪ Designed to: ▪ prevent iron deficiency ▪ maintain healthy iron levels ▪ Unique formulation: ▪ chewable ▪ pleasant taste ▪ 45 mg elemental iron ▪ supportive vitamins for iron health ▪ Launched in Canad
Slide 13: NEW in 2023 - Inofolic
NEW in 2023 - Inofolic® ▪ Launched in Canada in August 2023 ▪ New treatment option for women with Polycystic Ovary Syndrome (PCOS), an endocrine disorder which can cause: ▪ Insulin resistance ▪ Infertility ▪ Menstrual dysfunction ▪ Skin manifestations ▪ Hirsutism ▪ Alopecia ▪ Unique soft-gel capsule
Slide 14: NEW in 2023 - Gelclair
NEW in 2023 - Gelclair® ▪ In-licensed by BioSyent in December 2022 ▪ Oncology supportive care product for relief of oral mucositis ▪ Frequently experienced by cancer patients undergoing radiation or chemotherapy ▪ Protective concentrated gel which adheres to the mucosa of the mouth, providing: ▪ Fas
Slide 15: Growth Drivers
Growth Drivers Management of symptoms of PCOS Oncology supportive care product for Oral Mucositis FeraMAX® Pd Platform – Life Cycle Strategy In development HRT agent for menopause therapy Acquisition and in-licensing – ongoing 15 | www.biosyent.com | TSXV: RX
Slide 16: Cash Balance & Return on Equity
Cash Balance & Return on Equity (“RoE”) 30,000 25% • Zero Debt 28,212 28,696 28,687 25,000 21% 19% 20% • 2023 Cash from Operations 17% of $5.1M 20,000 15% • 2023 NCIB share buybacks: 15,000 $3.1 M CAD (000's) RoE % 10% 10,000 • 2023 Dividends of $1.9M 5,000 5% • Dec 31/23 Working Capital of $30.3M 0
Slide 17: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification Cash: Dividends $28.7M Growth & Diversification Debt: Share $0M Buybacks Excess capital may also be returned to shareholders: • Quarterly Dividends – Q4’22 – Q1’24 = $ 2.9 M to date (
Slide 18: Stock Information
Stock Information As at March 11, 2024 Exchange & Trading Symbol 0% TSXV: RX Mar 11, 2024 Closing Stock Price (CAD) $8.60 52 Week Hi/Low: $9.26 / $7.03 Issued Common Shares: 11,820,945 Treasury – RSU Shares in Trust (203,766) Outstanding Common Shares: 11,617,179 Options Outstanding 154,947 RSUs Out
Slide 19: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 19 | www.biosyent.com | TSXV: RX